Xencor reports Q1 EPS (4c), consensus (67c) » 16:0505/0505/05/21
Reports Q1 revenue…
Reports Q1 revenue $34.0M, consensus $16.45M. Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations into 2024. Xencor expects to end 2021 with between $425 million and $475 million in cash, cash equivalents and marketable securities. "We continue to expand and mature our clinical portfolio of XmAb(R) drug candidates, recently initiating a Phase 1 study for our second cytokine program, XmAb564, a wholly owned IL-2-Fc fusion protein, in healthy volunteers. We engineered this molecule to preferentially activate regulatory T cells, an emerging mechanism for treating patients with autoimmune diseases," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "Additionally, at the AACR meeting, we presented preclinical data from multiple early-stage programs that highlight our protein engineering expertise with our third cytokine, a wholly owned IL-12-Fc fusion protein, as well as the potential of our CD28 platform and XmAb 2+1 bispecific antibody format. Looking ahead, we will continue to present maturing data from our clinical-stage programs, and we have plans to initiate several additional clinical studies this year and early 2022, including a Phase 2 study in prostate cancer with XmAb717, our PD-1 x CTLA-4 bispecific antibody."
|Over a week ago|
Xencor doses first subject in ph1 study of XmAb564 » 16:1104/2804/28/21
Xencor announced that the…
Xencor announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical study of XmAb564, an engineered IL-2-Fc cytokine in development as a potential treatment for patients with autoimmune diseases. The study will evaluate the safety and tolerability of XmAb564, administered subcutaneously in healthy adult volunteers.
Xencor management to meet virtually with Wedbush » 04:5504/2204/22/21
Virtual Meetings to be…
Virtual Meetings to be held April 21-22 hosted by Wedbush.
Xencor management to meet virtually with Wedbush » 08:4204/2104/21/21
Virtual Meetings to be…
Virtual Meetings to be held April 21-22 hosted by Wedbush.
Xencor presents data from preclinical XmAb Bispecific antibody/cytokine programs » 15:3404/1104/11/21
Xencor announced the…
Xencor announced the presentation of new data from multiple preclinical XmAb bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research Annual Meeting, being held virtually April 10-15, 2021. According to Abstract 1743, "IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents," IL-12 is a potent proinflammatory cytokine produced by activated antigen-presenting cells, and it leads to proliferation of T cells and NK cells and increased cytotoxicity through high levels of interferon gamma signaling. As a potent immune stimulating protein, IL-12 can have a significant effect on shrinking tumors; however, prior clinical studies have demonstrated it to have a narrow therapeutic window, limiting potential response rates. Xencor's IL-12-Fc cytokine program builds on the company's prior work with IL-15-Fc cytokines in oncology, where reduced potency led to improved pharmacokinetics, pharmacodynamics and tolerability in preclinical studies. IL-12-Fc fusions were engineered with reduced potency in order to improve potential tolerability, slow receptor-mediated clearance and prolong the molecules' half-lives, compared to native IL-12. The potency-reduced IL-12-Fc fusions demonstrated significant anti-tumor activity in vivo concurrent with activation and proliferation of CD8+ T cells and increased levels of interferon gamma in serum. In non-human primates, the engineered cytokines had an improved pharmacokinetic profile and therapeutic window compared to a native cytokine-Fc fusion, with superior exposure, a more gradual dose response and similar levels of cytokine production in serum. According to Abstract: 1880, "PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors," Xencor engineered PD-L1 x CD28 bispecific antibodies to provide conditional co-stimulation of T cells, activating them when bound to tumor cells. PD-L1, which is expressed on many types of tumors, suppresses anti-tumor responses by the immune system and has been shown to directly inhibit CD28 co-stimulation. A PD-L1 x CD28 bispecific antibody, therefore, may promote CD28 co-stimulation and simultaneously block CD28's suppression by PD-L1. In vitro, the combination of the PD-L1 x CD28 and a CD3 T cell engager enhanced T cell activation and proliferation compared to the CD3 bispecific alone, as designed. PD-L1 x CD28 also enhanced the interaction between T cells and antigen presenting cells and exhibited strong CD28-dependent anti-tumor activity in mice. PD-L1 x CD28 was well tolerated in non-human primates and exhibited favorable pharmacokinetics. According to Abstract: 1860, "Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells," Claudin-6 is a tumor-associated antigen overexpressed in ovarian cancer and other solid tumors, and its differential expression in cancerous tissue makes CLDN6 an intriguing target for CD3 bispecific antibodies. Many members of the claudin family, which are small transmembrane proteins, have high sequence identity, which complicates selectivity among claudins. CLDN6 x CD3 bispecific antibodies were engineered in the XmAb 2+1 format, and the tumor binding domain was further engineered for improved selectivity of CLDN6 over similar claudin family members, such as CLDN9. In preclinical models, CLDN6 x CD3 bound more preferentially to tumor cells compared to cell lines with normal tissue CLDN9 expression levels. Lead candidates demonstrated reversal of tumor growth in human-cell engrafted mouse models of ovarian cancer. Further data from non-human primate studies demonstrated the candidates were well-tolerated with favorable pharmacokinetic profiles. According to Abstract: 1831, "Affinity tuned XmAb 2+1 GPC3 x CD3 bispecific antibodies demonstrate selective activity in liver cancer models," GPC3 is an antigen associated with hepatocellular carcinoma, squamous cell carcinoma of the lung and other cancers. Under certain conditions, GPC3 can trigger Wnt signaling and promote tumor proliferation. Despite a favorable expression profile, unfavorable tolerability has been reported from multiple clinical studies evaluating CAR-T therapy and T cell engaging bispecific antibodies that target GPC3. GPC3 x CD3 bispecific antibodies in the XmAb 2+1 format selectively recruited T cells to kill high GPC3-expressing cancer cells and avoided cytotoxicity to a low GP3C-expressing cell line. A comparison of GPC3 x CD3 bispecific antibodies with the XmAb 2+1 format and first-generation T cell engagers demonstrated similar anti-tumor activity and immune cell proliferation in vitro.
|Over a month ago|
Barclays to hold a virtual conference » 10:0603/1003/10/21
FRLN, REGN, ICLR, CI, CLLS, PTCT, THC, BKD, GOCO, AXNX, GTS, QDEL, LHCG, KIN, XNCR, TNDM, UHS, AMRX, RARE
Global Healthcare Virtual…
Global Healthcare Virtual Conference 2021 will be held on March 8-11.
Xencor, UCLA TDG collaborate to develop XmAb therapeutics » 05:1202/2502/25/21
Xencor and UCLA…
Xencor and UCLA Technology Development Group, or UCLA TDG, announced an agreement to develop novel therapeutic antibodies, pairing novel targets proposed by scientists at UCLA and utilizing Xencor's modular suite of XmAb technology platforms. Xencor and UCLA have established a streamlined framework to select promising biology, perform collaborative research and license intellectual property. Xencor's XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures, such as bispecific antibodies and engineered cytokines, or amplification of natural immune functions, such as extending circulating half-life or enhancing immune cell cytotoxicity. Xencor and its pharmaceutical partners are now advancing 20 clinical-stage XmAb-engineered drug candidates for the treatment of patients with life-threatening and debilitating diseases. Two of these antibodies have been approved by the U.S. FDA, one for the treatment of patients with rare blood disorders and the other for an aggressive form of non-Hodgkin lymphoma. The UCLA Technology Development Group, the campus' gateway to innovation, research and entrepreneurship, will work with faculty to propose potential antibody drug candidates. For selected candidates, the collaborators will use a framework with predefined terms to enter sponsored research agreements and potential license agreements.
Xencor remains a top pick for 2021 at Piper Sandler » 13:5302/2402/24/21
Piper Sandler analyst…
Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Xencor with a $60 price target following the company's Q4 results. Xencor ended 2020 with cash of $604M and continues to escalate and expand the Phase I DUET-1 study of XmAb717, Tenthoff tells investors in a research note. The analyst sees continued development in neuroendocrine tumors, as well as merkel cell and small cell lung cancers, and says Xencor remains a top pick for 2021.
Xencor price target raised to $59 from $48 at RBC Capital » 08:3902/2402/24/21
RBC Capital analyst…
RBC Capital analyst Gregory Renza raised the firm's price target on Xencor to $59 from $48 and keeps an Outperform rating on the shares after its Q4 earnings and liquidity update. The company is following a data-oriented development strategy, and he expects several data updates and trial initiations from its pipeline, which should drive a steady value appreciation in Xencor shares over the year, the analyst tells investors in a research note.
Xencor upgraded to Outperform from Market Perform at Raymond James » 07:3302/2402/24/21
Raymond James analyst…
Raymond James analyst Dane Leone upgraded Xencor (XNCR) to Outperform from Market Perform with a $58 price target. Leone believes a combination of plamotamab plus Monjuvi creates a direct commercial angle within an increasingly crowded field of CD20 bispecific antibodies and that the XmAb306 program in partnership with Genentech (RHHBY) is not currently reflected within valuation and could be nearing disclosure of initial clinical data during 2021, the analyst tells investors in a research note. Additionally, Leone thinks the validated protein engineering platform funded by royalties provides capital efficient optionality for earlier programs within oncology and immunology.